RxSight (RXST) Net Income towards Common Stockholders (2020 - 2026)
RxSight's (RXST) quarterly Net Income towards Common Stockholders came in at -$12.1 million in Q2 2026, down 2.64% on a YoY basis from -$12.4 million in Q2 2025, and up 23.84% quarter-over-quarter from -$15.9 million in Q1 2026.
Powered by 
Analysis
RxSight (RXST) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
RxSight (RXST) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$12.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 2.64% year-over-year to -$12.1 million; the trailing twelve-month figure through Jun 2026 stood at -$38.7 million (down 46.4% YoY), and the FY2025 full-year result was -$30.7 million, down 23.66% from the prior year.
- Net Income towards Common Stockholders grew to -$12.1 million in Q2 2026 per RXST's latest filing, from -$15.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.0 million in Q4 2023 and bottomed at -$17.6 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$9.5 million across 5 years, with a median of -$10.8 million in 2025.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders surged 165.78% in 2023, then plunged 588.06% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$1.6 million in 2022, then soared by 165.78% to $1.0 million in 2023, then slumped by 112.84% to -$134000.0 in 2024, then slumped by 588.06% to -$922000.0 in 2025, then sank by 1212.04% to -$12.1 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$12.1 million, -$15.9 million, and -$922000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.90 Bn | 21.43 Bn | 684.20 Mn | 201.00 Mn |
| 10 | RxSight | 265.31 Mn | -138.93 Mn | - | -12.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.10 Mn |
| Mar 31, 2026 | -15.88 Mn |
| Dec 31, 2025 | -922,000.00 |
| Sep 30, 2025 | -9.82 Mn |
| Jun 30, 2025 | -11.79 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -134,000.00 |
| Sep 30, 2024 | -6.34 Mn |
| Jun 30, 2024 | -6.08 Mn |
| Mar 31, 2024 | -9.10 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | -12.42 Mn |
| Jun 30, 2023 | -13.80 Mn |
| Mar 31, 2023 | -13.21 Mn |
| Dec 31, 2022 | -1.59 Mn |
| Sep 30, 2022 | -16.82 Mn |
| Jun 30, 2022 | -16.73 Mn |
| Mar 31, 2022 | -17.60 Mn |
| Dec 31, 2021 | -15.73 Mn |
| Sep 30, 2021 | -12.67 Mn |